Skip to content

Study · Observational study · n = 31 · 2019

3 results

A pharmacist-run anabolic osteoporosis clinic: An abaloparatide descriptive report.

McGreevy JL, Kane MP, Busch RS, Bakst G, ElDeiry S

Journal of the American Pharmacists Association : JAPhA14 May 2019

PMID31101442 (opens in a new tab)DOI10.1016/j.japh.2019.03.017 (opens in a new tab)PepBankPUB-31101442
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanObservational studySafety outcome

    In the clinic, five patients discontinued abaloparatide because of adverse effects.

    In plain wordsIn the clinic, five patients stopped abaloparatide because of adverse effects.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    Direction not reportedDiscontinuation due to adverse effects
    Study

    n = 31

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Measurements

    Discontinuations
    5 patients
    adverse effects

    Source sentences

    Summary
    An additional 5 patients discontinued abaloparatide therapy owing to adverse effects.
    1 context sentence
    Summary · context
    The population predominately consisted of postmenopausal white women.

Studies that did not test the peptide alone2

In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Abaloparatide (Tymlos).

  1. 02HumanNot a test of Abaloparatide (Tymlos) aloneObservational studyOther

    In the osteoporosis clinic, 31 of 52 referred patients initiated abaloparatide therapy.

    In plain wordsIn the osteoporosis clinic, 31 of 52 referred patients started abaloparatide therapy.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    Not applicableTreatment initiation
    Study

    n = 52

    Outcome group
    Patterns of use · Whole body

    Measurements

    Initiation
    59.6%
    referred patients
    Initiation
    31 patients
    referred patients

    Source sentences

    Summary
    During its first year of availability, 52 patients were referred for abaloparatide therapy. Of these, 31 patients (59.6%) initiated treatment.
    1 context sentence
    Summary · context
    The population predominately consisted of postmenopausal white women.

    In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).

  2. 03HumanNot a test of Abaloparatide (Tymlos) aloneObservational studyOther

    In the clinic, patients did not initiate abaloparatide because of cost, therapy concerns, or contraindications.

    In plain wordsIn the clinic, cost, treatment concerns, and contraindications prevented some patients from starting abaloparatide.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    Not applicableReasons for noninitiation
    Study

    n = 21

    Outcome group
    Patterns of use · Whole body

    Measurements

    Noninitiation due to cost
    9 patients
    noninitiators
    Noninitiation due to therapy concerns
    8 patients
    noninitiators
    Noninitiation due to contraindication
    4 patients
    noninitiators

    Source sentences

    Summary
    Twenty-one patients did not initiate abaloparatide therapy owing to cost (9), concerns of therapy (8), or contraindication to therapy (4).
    1 context sentence
    Summary · context
    The population predominately consisted of postmenopausal white women.

    In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.